Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Depreciation and Depletion (2020 - 2025)

Historic Depreciation and Depletion for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $555000.0.

  • Tango Therapeutics' Depreciation and Depletion fell 750.0% to $555000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 449.3%. This contributed to the annual value of $2.5 million for FY2024, which is 351.97% up from last year.
  • As of Q3 2025, Tango Therapeutics' Depreciation and Depletion stood at $555000.0, which was down 750.0% from $625000.0 recorded in Q2 2025.
  • Tango Therapeutics' 5-year Depreciation and Depletion high stood at $675000.0 for Q2 2024, and its period low was $200000.0 during Q3 2021.
  • For the 5-year period, Tango Therapeutics' Depreciation and Depletion averaged around $484210.5, with its median value being $600000.0 (2023).
  • As far as peak fluctuations go, Tango Therapeutics' Depreciation and Depletion skyrocketed by 12007.72% in 2022, and later plummeted by 750.0% in 2025.
  • Over the past 5 years, Tango Therapeutics' Depreciation and Depletion (Quarter) stood at $259000.0 in 2021, then surged by 120.08% to $570000.0 in 2022, then grew by 7.89% to $615000.0 in 2023, then dropped by 2.44% to $600000.0 in 2024, then dropped by 7.5% to $555000.0 in 2025.
  • Its Depreciation and Depletion was $555000.0 in Q3 2025, compared to $625000.0 in Q2 2025 and $622000.0 in Q1 2025.